Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
JCI Insight ; 6(7)2021 04 08.
Artigo em Inglês | MEDLINE | ID: mdl-33729999

RESUMO

Autoimmune diseases are characterized by a breakdown of immune tolerance partly due to environmental factors. The short-chain fatty acid acetate, derived mostly from gut microbial fermentation of dietary fiber, promotes antiinflammatory Tregs and protects mice from type 1 diabetes, colitis, and allergies. Here, we show that the effects of acetate extend to another important immune subset involved in tolerance, the IL-10-producing regulatory B cells (B10 cells). Acetate directly promoted B10 cell differentiation from mouse B1a cells both in vivo and in vitro. These effects were linked to metabolic changes through the increased production of acetyl-coenzyme A, which fueled the TCA cycle and promoted posttranslational lysine acetylation. Acetate also promoted B10 cells from human blood cells through similar mechanisms. Finally, we identified that dietary fiber supplementation in healthy individuals was associated with increased blood-derived B10 cells. Direct delivery of acetate or indirect delivery via diets or bacteria that produce acetate might be a promising approach to restore B10 cells in noncommunicable diseases.


Assuntos
Acetatos/metabolismo , Acetatos/farmacologia , Artrite Experimental/terapia , Linfócitos B Reguladores/efeitos dos fármacos , Fibras na Dieta/farmacologia , Acetatos/sangue , Acetilcoenzima A/metabolismo , Acetilação , Animais , Artrite Experimental/imunologia , Linfócitos B Reguladores/fisiologia , Linfócitos B Reguladores/transplante , Diferenciação Celular/efeitos dos fármacos , Ácidos Graxos Voláteis/metabolismo , Ácidos Graxos Voláteis/farmacologia , Feminino , Humanos , Interleucina-10 , Masculino , Camundongos Endogâmicos C57BL , Camundongos Mutantes , Neutrófilos/citologia , Neutrófilos/efeitos dos fármacos , Receptores Acoplados a Proteínas G/genética
3.
J Frailty Aging ; 5(4): 233-241, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27883170

RESUMO

The Région Languedoc Roussillon is the umbrella organisation for an interconnected and integrated project on active and healthy ageing (AHA). It covers the 3 pillars of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA): (A) Prevention and health promotion, (B) Care and cure, (C) and (D) Active and independent living of elderly people. All sub-activities (poly-pharmacy, falls prevention initiative, prevention of frailty, chronic respiratory diseases, chronic diseases with multimorbidities, chronic infectious diseases, active and independent living and disability) have been included in MACVIA-LR which has a strong political commitment and involves all stakeholders (public, private, patients, policy makers) including CARSAT-LR and the Eurobiomed cluster. It is a Reference Site of the EIP on AHA. The framework of MACVIA-LR has the vision that the prevention and management of chronic diseases is essential for the promotion of AHA and for the reduction of handicap. The main objectives of MACVIA-LR are: (i) to develop innovative solutions for a network of Living labs in order to reduce avoidable hospitalisations and loss of autonomy while improving quality of life, (ii) to disseminate the innovation. The three years of MACVIA-LR activities are reported in this paper.


Assuntos
Envelhecimento , Política de Saúde , Promoção da Saúde , Vida Independente , Medicina Preventiva , Acidentes por Quedas/prevenção & controle , Idoso , Idoso de 80 Anos ou mais , Doença Crônica , Comorbidade , União Europeia , França , Hospitalização , Humanos , Múltiplas Afecções Crônicas , Saúde Bucal , Autonomia Pessoal , Polimedicação , Qualidade de Vida , Doenças Respiratórias
4.
Arthritis Rheumatol ; 68(4): 977-85, 2016 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-26606524

RESUMO

OBJECTIVE: To define parameters predictive of lymphoma development in patients with primary Sjögren's syndrome (SS). METHODS: A multicenter case-control survey was performed to identify predictors of lymphoma. Cases were patients who developed lymphoma after diagnosis of primary SS and were mainly recruited through the Club Rhumatismes et Inflammation network. For each case, 2 controls (matched for disease duration and age) were randomly selected among patients with primary SS and without lymphoma. Cases and controls were compared using univariate analysis and then using multivariate analysis to identify independent predictors of lymphoma. RESULTS: One hundred one patients with primary SS and lymphoma were included. Eighty-seven patients were women (86.1%), and the mean ± SD age at lymphoma diagnosis was 57.4 ± 12.6 years. The most frequent histologic type was B cell non-Hodgkin's lymphoma (NHL) in 99 of 101 patients, with marginal-zone lymphoma in 76 of the 99 patients (76.8%) including 58 (58.6%) with lymphoma of the mucosa-associated lymphoid tissue type. Lymphomas were most frequently located in the salivary glands (43 patients). A specific treatment was initiated at diagnosis in 87 patients with B cell NHL, and 61 patients (61.6%) achieved complete sustained remission after the first line of treatment. In the multivariate analysis, salivary gland enlargement, the presence of rheumatoid factor (RF), low C4, cryoglobulinemia, lymphopenia, and disease activity according to the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (excluding the lymphoma domain) were found to be predictors of lymphoma. No previous treatment for primary SS was associated with any effect on lymphoma occurrence. CONCLUSION: In addition to previously known factors predictive of lymphoma occurrence, the independent roles of RF and disease activity were demonstrated in this case-control study of primary SS-associated lymphoma. Our findings highlight the roles of chronic antigenic stimulation and disease activity in the development of this severe complication.


Assuntos
Complemento C4/imunologia , Crioglobulinemia/epidemiologia , Neoplasias Pulmonares/epidemiologia , Linfoma/epidemiologia , Linfopenia/epidemiologia , Fator Reumatoide/imunologia , Neoplasias das Glândulas Salivares/epidemiologia , Síndrome de Sjogren/epidemiologia , Neoplasias Cutâneas/epidemiologia , Adulto , Idoso , Estudos de Casos e Controles , Feminino , França/epidemiologia , Doença de Hodgkin/epidemiologia , Humanos , Leucemia Linfocítica Crônica de Células B/epidemiologia , Linfoma de Células B/epidemiologia , Linfoma de Zona Marginal Tipo Células B/epidemiologia , Linfoma Difuso de Grandes Células B/epidemiologia , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Micose Fungoide/epidemiologia , Estudos Retrospectivos , Índice de Gravidade de Doença , Síndrome de Sjogren/imunologia , Reino Unido/epidemiologia
5.
Ann Cardiol Angeiol (Paris) ; 61(2): 111-7, 2012 Apr.
Artigo em Francês | MEDLINE | ID: mdl-21885031

RESUMO

Mortality in rheumatoid arthritis (RA) is doubled when compared to the general population. This excess in mortality can be explained in half of cases by cardiovascular (CV) events. The risk of myocardial infarction is increased by about 60% in RA. Mortality secondary to cerebrovascular stroke is increased by 50% even if the incidence of stroke is not increased. Indeed, the risk of fatal CV events is increased in RA when compared to the general population. The increased CV risk cannot be explained only by traditional CV risk factors, even if smoking and changes in lipid profile may be implied. It is mainly related to the chronic inflammatory condition that causes many metabolic disturbances. Other parameters such as treatments used in RA also play a role. Thus, it is essential for proper management of RA patients to be aware of this risk and to treat any modifiable CV risk factors.


Assuntos
Artrite Reumatoide/epidemiologia , Doenças Cardiovasculares/epidemiologia , Anti-Inflamatórios não Esteroides/administração & dosagem , Anti-Inflamatórios não Esteroides/efeitos adversos , Antirreumáticos/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Humanos , Inflamação/epidemiologia , Metotrexato/uso terapêutico , Fatores de Risco , Acidente Vascular Cerebral/epidemiologia , Fator de Necrose Tumoral alfa/antagonistas & inibidores
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...